开拓药业-B2022年中期报告

开拓药业有限公司* KINTORPHARMACEUTICALLIMITED (IncorporatedintheCaymanIslandswithlimitedliability) （于开曼群岛注册成立的有限责任公司） StockCode股份代号:9939 2022 INTERIMREPORT 中期报告 *Foridentificationpurposeonly仅供识别 https://www.kintor.com.cn TableofContents 目录 2CorporateInformation 公司资料 5FinancialandBusinessHighlights 财务与业务摘要 8ManagementDiscussionandAnalysis 管理层讨论与分析 37InterimCondensedConsolidatedStatementofComprehensiveIncome 中期简明综合全面收益表 38InterimCondensedConsolidatedStatementofFinancialPosition 中期简明综合财务状况表 40InterimCondensedConsolidatedStatementofChangesinEquity 中期简明综合权益变动表 41InterimCondensedConsolidatedStatementofCashFlows 中期简明综合现金流量表 43NotestotheCondensedConsolidatedInterimFinancialInformation 简明综合中期财务资料附注 72OtherInformation 其他资料 88Definitions 释义 CORPORATEINFORMATION 公司资料 BoardofDirectors ExecutiveDirectors Dr.YouzhiTONG(ChairmanoftheBoardandChiefExecutiveOfficer) Ms.YanLU Non-executiveDirectors Mr.WeipengGAOMs.GeqiWEI Mr.ChengweiLIU IndependentNon-executiveDirectors Dr.MichaelMinXU Mr.WallaceWaiYimYEUNGProf.LiangTONG AuditCommittee Mr.WallaceWaiYimYEUNG(Chairman) Dr.MichaelMinXUMr.ChengweiLIU NominationCommittee Dr.YouzhiTONG(Chairman)Mr.WallaceWaiYimYEUNGDr.MichaelMinXU RemunerationCommittee Dr.MichaelMinXU(Chairman) Dr.YouzhiTONGProf.LiangTONG JointCompanySecretaries Ms.YanLU Mr.WaiChiuWONG 董事会 执行董事 童友之博士（董事会主席兼行政总裁）卢燕女士 非执行董事高维鹏先生卫舸琪女士刘澄伟先生 独立非执行董事 徐敏博士杨怀严先生童亮教授 审核委员会 杨怀严先生（主席）徐敏博士 刘澄伟先生 提名委员会 童友之博士（主席）杨怀严先生 徐敏博士 薪酬委员会 徐敏博士（主席）童友之博士 童亮教授 联席公司秘书 卢燕女士黄伟超先生 CorporateInformation(Continued) 公司资料（续） AuthorisedRepresentatives Dr.YouzhiTONGMr.WaiChiuWONG 授权代表 童友之博士 黄伟超先生 RegisteredOffice CricketSquare HutchinsDrive,POBox2681GrandCayman,KY1-1111CaymanIslands HeadOfficeandPrincipalPlaceofBusinessinChina No.20SongbeiRoadSuzhouIndustrialParkSuzhou JiangsuPRC PrincipalPlaceofBusinessinHongKong Suite2007,20thFloorTower2,TheGatewayHarbourCity KowloonHongKong LegalAdviser AshurstHongKong11/FJardineHouse1ConnaughtPlaceCentral HongKong Auditor PricewaterhouseCoopers CertifiedPublicAccountantsandRegisteredPublicInterestEntityAuditor 22/FPrince’sBuildingCentral HongKong 注册办事处 CricketSquare HutchinsDrive,POBox2681GrandCayman,KY1-1111CaymanIslands 中国总办事处及主要营业地点 中国江苏省苏州市 苏州工业园区淞北路20号 香港主要营业地点 香港九龙海港城 港威大厦第二座 20楼2007室 法律顾问 亚司特律师事务所香港 中环 康乐广场1号怡和大厦11楼 核数师 罗兵咸永道会计师事务所 执业会计师及注册公众利益实体核数师 香港中环 太子大厦22楼 CorporateInformation(Continued) 公司资料（续） PrincipalShareRegistrarandTransferOffice ConyersTrustCompany(Cayman)LimitedCricketSquare HutchinsDrive,POBox2681GrandCayman,KY1-1111CaymanIslands HongKongShareRegistrar ComputershareHongKongInvestorServicesLimitedShops1712-1716,17thFloor HopewellCentre 183Queen’sRoadEastWanchai HongKong PrincipalBanks ShanghaiPudongDevelopmentBankSuzhouBranchWuzhongSub-branch ChinaConstructionBankSuzhouIndustrialParkSub-branch Company’sWebsite www.kintor.com.cn BoardLotSize 500Shares StockCode 9939 主要股份过户登记处 ConyersTrustCompany(Cayman)LimitedCricketSquare HutchinsDrive,POBox2681GrandCayman,KY1-1111CaymanIslands 香港证券登记处 香港中央证券登记有限公司香港 湾仔 皇后大道东183号合和中心 17楼1712-1716号铺 主要往来银行 上海浦东发展银行苏州分行吴中支行 中国建设银行苏州工业园区支行 公司网站 www.kintor.com.cn 每手买卖单位 500股股份 股份代号 9939 FINANCIALANDBUSINESSHIGHLIGHTS 财务与业务摘要 FinancialHighlights •Wedidnotgenerateanyrevenueforthesixmonthsended30June2022andthesixmonthsended30June2021. •Ouradjustedlossafteraddingbackshare-basedcompensationexpensesfortheEmployeeIncentiveSchemeincreasedbyRMB168.7millionorapproximately56.3%fromRMB299.9millionforthesixmonthsended30June2021toRMB468.6millionforthesixmonthsended30June2022. •OurR&DcostsincreasedbyRMB178.9millionorapproximately63.4%fromRMB282.2millionforthesixmonthsended30June2021toRMB461.1millionforthesixmonthsended30June2022. •TheBoarddoesnotrecommendanypaymentofinterimdividendforthesixmonthsended30June2022. BusinessHighlights Since2022,wehavebeenmakingsteadyprogresswithrespecttoourpipelineandbusinessoperations,includingthefollowingmilestonesandachievements: Pruxelutamide(GT0918) COVID-19Indication •On10February2022,thefirstpatientinChinawasenrolledanddosedinthemulti-regionalregistrationalphaseIIIclinicaltrialofPruxelutamideforthetreatmentofCOVID-19patientswithmildtomoderatesymptoms(NCT04869228).ThefirstpatientenrollmentofthisclinicaltrialinBrazilwascompletedon4August2021. •On6April2022,theCompanyannouncedthetop-lineresultsfromtheU.S.andglobalregistrationalphaseIIIclinicaltrialofPruxelutamideonpatientswithmildtomoderateCOVID-19(NCT04870606).Pruxelutamideeffectivelyreducedhospitalisation/mortalitywithin28days;forpatientswhocompletedthemedicationformorethan7days,theprotectionratewas100%(P<0.02).Pruxelutamidesignificantlyreducedthehospitalisation/mortalityrateamongpatientswithhighriskfactors(especiallyinthemiddleandhighagegroup),andtheprotectionratewas100%(P<0.02);PruxelutamidesignificantlyandcontinuouslyreducedtheCOVID-19viralload,andevidentlyimprovedCOVID-19relatedsymptoms,whichisofstatisticalsignificance.Pruxelutamidewasgenerallywelltolerated,safeandcontrollable,andnoseriousadverseevents(SAE)werefoundinthestudy. 财务摘要 •截至2022年6月30日止六个月及截至2021年6月 30日止六个月，我们并无产生任何收益。 •我们经加回雇员激励计